|
|
Article: Double First From FDA for Evolutec and Cobra.
- Article from:
- Business Wire
- Article date:
- November 6, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
BIOWIRE2K
OXFORD & KEELE, England--(BUSINESS WIRE)--Nov. 6, 2002
- Evolutec Receives First IND Status From FDA for rEV131 & Cobra
Gains First FDA Approval for a Protein Manufactured by the
Company
Evolutec, the biotechnology company specialising in the discovery and development of novel therapeutic products from parasites is to begin Phase I/II clinical trials with rEV131, its treatment for allergic and inflammatory diseases, in North America in the next few weeks.